Switzerland· 65906001
Taltz 80 mg, solution injectable en seringue préremplie
A ixekizumab product, registered in Switzerland by Eli Lilly (Suisse) SA and dispensed under Swissmedic category B. The same ATC class is registered in 14 of our 19 countries.
Checked against the register on
Informational only — not a medical device.
Where it is registered
Ixekizumab is registered in 14 of 19 countries.
Countries holding a registration under ATC L04AC13 (ixekizumab), each read from that country’s own register.
- This record: Switzerland
- 9 of them publish a price we can compare per daily dose
Ixekizumab · ATC L04AC13
14 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Icelandprice
- Ireland
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of ixekizumab costs, country by country.
Normalised to the WHO defined daily dose (2.9 mg), so markets compare like for like.
- Switzerland: $44.39 per daily dose (median across products in the class)
- Public list prices, converted to USD at the rate date shown
Ixekizumab · price per daily dose (2.9 mg)
USD · FX 28 Sept 2026
- CH Switzerland$44.39
The record
At a glance
- Manufacturer
- Eli Lilly (Suisse) SA
- Country
- Switzerland (CH)
- ATC code
- L04AC13
- ATC class
- Ixekizumab
- Defined daily dose
- 2.9 mg, P
- Swissmedic category
- B
- Reimbursed
- No
- Last checked
- June 26, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
149 interactions on record for ixekizumab.
Graded by severity as the source publishes them — 27 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Ixekizumab · interactions on record
149 records
- 27 severe
- 115 moderate
- 7 minor
Most severe, free to view
- CladribineL01BB04severe
- Talimogene laherparepvecL01XL02severe
- Talimogen laherparepvecL01XX51severe
- LeflunomidL04AA13severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same class
Other records under L04AC13
Ixekizumab, as other registers publish it.
- PolandTaltzEli Lilly and Company (Ireland) Limited
- FinlandTaltzEli Lilly and Company (Ireland) Limited
- IcelandTaltzEli Lilly and Company (Ireland) Limited
- DenmarkTaltzEli Lilly and Company (Ireland) Limited
- PolandTaltzEli Lilly and Company (Ireland) Limited
- DenmarkTaltzEli Lilly and Company (Ireland) Limited
- FinlandTaltzEli Lilly and Company (Ireland) Limited
- NorwayTaltzEli Lilly and Company (Ireland) Limited
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of the issuing authority. This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/cd0b5cc6-a4d5-4b66-a939-972162fd16e6 GET /v1/drugs/cd0b5cc6-a4d5-4b66-a939-972162fd16e6?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"source": "swissmedic_auth",
"heilmittelcode": "Biotechnologika"
}See everything about ixekizumab.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.